The effects of tumor necrosis factor inhibition on carcinogenesis and tumor progression are incompletely understood. In 2009, an analysis by the FDA suggested an increased risk of cancer in children and adolescents with systemic inflammatory diseases treated with those agents. By contrast, a recent population-based assessment of cancer risk did not find an overall elevation with anti-TNF treatment, and no increase with longer follow-up times.
- Anja Strangfeld
- Angela Zink
